RBC Capital analyst Ben Hendrix lowered the firm’s price target on Humana to $507 from $599 but keeps an Outperform rating on the shares. The company’s negative Q4 pre-announcement was driven by lower than expected 2024 Medicare Advantage growth and higher Q4 utilization, but while the stock will likely be in the penalty box in the near-term, the resetting of intermediate EPS targets by management could also give the stock a floor, the analyst tells investors in a research note. RBC is cutting its FY24 EPS view to $28.97 from $31.54 and its FY25 view to $33.33 from $37.04.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HUM:
- Humana Forecasts Medicare Advantage Membership Growth
- 3 Best Stocks to Buy Now, 1/19/2024, According to Top Analysts
- Humana Stock (NYSE:HUM) Under $400 Looks Like a Great Deal
- Humana’s (NYSE:HUM) Bleak Q4 Forecast Sends Ripples Across the Industry
- Humana says emerging utilization trends are ‘impacting the industry broadly’
